authors
- Pollack, C
- Reilly, PA
- Verhamme, P
- Bernstein, R
- Dubiel, R
- Eikelboom, John
- Huisman, M
- Hylek, E
- Kam, C-W
- Kamphuisen, PW
- Kreuzer, J
- Levy, JH
- Sellke, F
- Steiner, T
- Wang, B
- Weitz, Jeffrey
Initial results of the re-verse AD trial: idarucizumab reverses the anticoagulant effects of dabigatran in patients in an emergency setting of major bleeding, urgent surgery, or interventions
Conferences
- Overview
- Research
- Additional Document Info
- View All
Overview
status
publication date
- June 1, 2015
has subject area
- 1102 Cardiorespiratory Medicine and Haematology (FoR)
- 1103 Clinical Sciences (FoR)
- Cardiovascular System & Hematology (Science Metrix)